medicinal chemistry

DIMERx, Inc. is a clinical-stage biopharmaceutical company developing first-in-class, covalently linked dimer-based therapeutics to address major public-health challenges in pain management and the opioid crisis. Its pipeline includes DMX-101 (buprenorphine dimer, Phase 2), DMX-201 (arginine-agmatine dimer, IND-enabling) and DMX-105 (acetaminophen dimer, IND-enabling). Development is supported by competitive NIH awards, including an $18M mandate.

clinical developmentcovalent dimerization technology platformdrug discovery and developmentpreclinical developmentregulatory strategy

Drug Discovery Alliances provides a pharmaceutical R&D platform backed by an integrated team of CMC consultants and a global network of preferred suppliers, driving programs from discovery phase to commercialization. Founded in 2001 by Deborah Minor, Ph.D., the company supports biotech and pharmaceutical companies with drug discovery, drug development, CMC consulting, and regulatory support.

analytical method developmentantibody manufacturingAPI manufacturingcatalysis screeningCMC consultingcrystallizationformulation developmentGMP auditingGMP manufacturingIND application preparationpreclinical developmentprocess researchregulatory supportsolid form screening

ENCUE is a Northwestern spinout developing novel modulators and therapeutics for neurodegenerative and psychiatric disorders. Its approach targets synaptic function and neuroplasticity to restore synaptic health and normal cognition, with a focus on the IGF2R receptor. The company reports six molecules currently in Phase 2/3 clinical trials.

clinical research and developmentdrug discoverytherapeutic development

Epigen Biosciences is a pharmaceutical company discovering innovative, proprietary drugs to address unmet medical needs. It develops small-molecule compounds including an LPA1 receptor antagonist, selective sigma-1 receptor ligands, p70 S6 kinase inhibitors, and PAM-IIs, targeting conditions such as diabetic kidney disease, NASH/MASH, idiopathic pulmonary fibrosis, Alzheimer's disease, ALS, Fragile X syndrome, and stroke. The company combines medicinal chemistry and drug development expertise with academic collaborations.

ADME property assessmentcomputational designdrug developmentfocused library synthesishit-to-lead and lead optimizationin silico drug discoveryscaffold-hoppingscreeningstrategic project management

Eradivir is a clinical-stage biotechnology company founded in March 2020 by Dr. Philip S. Low and Martin Low, based in West Lafayette, Indiana. It develops small molecules using its Bispecific Antigenic immuno-Therapy (BAiT) technology that target diseased cells and viruses, flagging them for clearance by the immune system. The company is developing therapies for influenza, RSV, and other serious diseases, including EV25 for influenza.

clinical developmentpreclinical developmentsmall molecule drug discoveryvirology research

Estrigenix Therapeutics, Inc. was formed in 2018 to develop and commercialize first-in-class therapeutics to treat and prevent hot flashes and dementia in post-menopausal women. It is a privately held pharmaceutical company working on a family of compounds to address menopause symptoms, moderating hot flashes and improving memory without the risks of breast cancer and stroke associated with traditional hormone replacement therapy, based on expertise in estrogen biology.

clinical trialsdrug discovery and developmentestrogen biology researchpharmacology

Eviogen Discovery is an innovation-driven Contract Research Organization (CRO) established in 2016, offering integrated drug discovery services and customized bio solutions to pharma, biotech, life-science industries and research organizations. It provides services from target discovery to lead candidate selection, including target ID and validation, hit-to-lead, lead optimization, and in-vitro safety and toxicology studies, with flexible FFS or FTE business models.

assay biologyFlow Cytometryhigh content imagingin vitro ADMEin vivo PKnext-generation sequencingprotein expression and purificationqPCRscreeningSPR (Biacore)stable cell line generation

Fedora Pharmaceuticals Inc. is a Canadian clinical-stage biotechnology company based in Edmonton, Alberta, founded in 2011. It discovers and develops novel antibacterial therapies to combat antimicrobial resistance (AMR). Its pipeline includes nacubactam, a β-lactamase inhibitor/enhancer, and FPI-2119, a first-in-class non-β-lactam penicillin-binding protein inhibitor. The company's team also discovered tazobactam.

antibiotic discoverydrug developmentlicensingpreclinical development

Ferdia Therapeutics is a San Diego-based, privately held biotechnology consulting LLC specializing in peptide drug discovery and development, with particular expertise in the design and optimization of long-acting peptide therapeutics. It provides end-to-end scientific and strategic consulting services to biotechnology and pharmaceutical companies, supporting programs from early discovery through preclinical evaluation and development.

biodistributionhalf-life extension strategiespeptide drug discoverypeptide ligand design and optimizationpharmacokinetic optimizationradiolabeling strategiesradiopharmaceutical pharmacologySAR analysisscreening strategy and hit identification consulting

INVENT Pharmaceuticals is a San Diego, CA-based company designing, discovering and developing novel small molecule therapeutics for complex chronic diseases, including cardiorenal, pulmonary, vascular, fibrotic and neurodegenerative diseases, neuroendocrine tumor, and neuropsychiatric disorders. It applies a precision drug design and discovery platform integrating medicinal chemistry, site-specific precision molecular modification, in vitro and in vivo pharmacology, and artificial intelligence.

AI-enabled discoverycomputational chemistryin vitro and in vivo pharmacologyprecision drug designsite-specific precision molecular modificationstructure-based design and optimization of small moleculestranslational pharmacology

IRBM is a preclinical drug discovery organization based in Rome, Italy, conducting small molecule, peptide and antibody programs from target validation through to a preclinical candidate, either as a full integrated program or as a single capability for clients. Its scientists have contributed to three approved drugs and delivered more than thirty preclinical candidates to partners.

ADMEantibody phage displayassay developmentBioinformaticsbiophysical characterizationcompound managementcomputational chemistryDMPKfunctional genomicshigh-content screeninghigh throughput screeningin vivo pharmacologymRNA displayNMRpeptide chemistrypeptide phage displayprotein productionstructural biologysynthetic chemistry

Kannalife Sciences, Inc., a subsidiary of Neuropathix, Inc., is a biopharmaceutical company focused on discovering, developing and commercializing breakthrough therapeutics targeting neuroinflammation, healthspan and neuropathic pain. Since 2010 it has been involved in research and development of synthetic cannabidiol (CBD) inspired therapeutics through pre-clinical drug discovery. Its lead candidate is KLS-13019, and it conducts R&D at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

drug developmentpre-clinical drug discoveryresearch and development